Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Regulation of Angiogenesis and Blood Supply

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Endoglin (CD105) overexpression is associated with an immunosuppressive tumor microenvironment in murine lung cancer models and human lung adenocarcinoma.

Scientific reports·2026

Same author

Targeted KRASG12V Degradation in vivo Elicits Lung Adenocarcinoma Regression with Subsequent Relapse from Dysregulated Proteolysis.

Cancer research·2026

Same author

Vascular growth patterns correlate with histological subtypes in human lung adenocarcinoma.

Experimental and molecular pathology·2026

Same author

Advancing lung cancer therapy - leveraging cell biology to improve immunotherapy and anti-angiogenic strategies.

Journal of cell science·2026

Same author

Learning to assess the fall risk in clinical nursing education: an interpretative study.

International journal of orthopaedic and trauma nursing·2025

Same author

Vascular Disruption Therapy as a New Strategy for Cancer Treatment.

International journal of molecular sciences·2025

Search research articles

Related Experiment Video

Updated: Oct 16, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Improved Immunotherapy Efficacy by Vascular Modulation.

Emma L Newport¹, Ana Rita Pedrosa¹, Alexandra Njegic¹

¹Centre for Tumour Microenvironment, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.

|October 23, 2021

Summary

Modulating tumor vasculature through anti-angiogenesis and vascular normalization can enhance cancer immunotherapy. Combining vessel targeting with immunotherapies like checkpoint blockade may improve T cell infiltration and patient response rates.

Keywords:

angiogenesis blood vessels immunotherapy vascular normalisation

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

A Modified Heterotopic Swine Hind Limb Transplant Model for Translational Vascularized Composite Allotransplantation VCA Research

A Modified Heterotopic Swine Hind Limb Transplant Model for Translational Vascularized Composite Allotransplantation VCA Research

Published on: October 14, 2013

Related Experiment Videos

Last Updated: Oct 16, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

A Modified Heterotopic Swine Hind Limb Transplant Model for Translational Vascularized Composite Allotransplantation VCA Research

A Modified Heterotopic Swine Hind Limb Transplant Model for Translational Vascularized Composite Allotransplantation VCA Research

Published on: October 14, 2013

Area of Science:

Oncology
Immunology
Vascular Biology

Background:

Cancer therapies include anti-angiogenesis and vascular normalization to modulate tumor vasculature.
Immunotherapies, such as immune checkpoint blockade and CAR T cell therapy, have improved cancer treatment but have limited response rates.
Poor T cell infiltration in tumors is linked to reduced immunotherapy efficacy.

Purpose of the Study:

To review strategies for modulating tumor vasculature to enhance cancer immunotherapy.
To explore the role of vasculature in T cell infiltration and activation within the tumor microenvironment.
To discuss the combination of vessel targeting strategies with immunotherapy for improved treatment outcomes.

Main Methods:

Literature review of studies on vessel modulation and immunotherapy.
Analysis of the impact of vascular normalization and anti-angiogenesis on tumor microenvironment.
Examination of T cell recruitment, infiltration, and activation in response to vascular targeting.

Main Results:

Vessel modulation strategies alter tumor oxygenation and immune cell infiltration.
Targeting vasculature can improve lymphocyte recruitment and T cell infiltration into tumors.
Combining vascular targeting with immunotherapy shows promise for enhancing treatment efficacy.

Conclusions:

Modulating tumor vasculature is a viable strategy to improve immunotherapy outcomes.
Vascular normalization and anti-angiogenesis can overcome resistance to immunotherapy by enhancing T cell infiltration.
Combination therapies targeting both tumor vasculature and immune checkpoints represent a promising frontier in cancer treatment.